Florian Fitzal - Concepedia

Author

Florian Fitzal

Also Known As

B Mlineritsch, F Fitzal, F. FITZAL, F. Fitzal, Fitzal F, Fitzal, Florian, Florian Fitzal, Franziska Fick, M Balic, Schrenk, Peter

341

Publications

9.6K

Citations

H-Index

Concepts

All Affiliations

Medical University of Vienna Comprehensive Cancer Center Vienna Austrian Breast & Colorectal Cancer Study Group Paracelsus Medical University Medical University of Graz

About

Florian Fitzal is an author at Medical University of Vienna specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	41	3.6K
2	Health Sciences	10	10	1.2K
3	Biomedical Engineering	3	3	147
4	Engineering	2	2	115
5	Public Health	2	2	68

Florian Fitzal

Publications

7.9K

Citations

H-Index

Page 1

	Year	Citations
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer Michael Gnant, Brigitte Mlineritsch, Walter Schippinger, New England Journal of Medicine	2009	1K
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors Martin Filipits, Margaretha Rudas, R. Jakesz, Clinical Cancer Research	2011	703
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial Michael Gnant, Georg Pfeiler, Peter Dubsky, The Lancet Breast OncologyOncologyClinical TrialsAdjuvant DenosumabPlacebo-controlled Trial	2015	543
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Michael Gnant, Brigitte Mlineritsch, G. Luschin-Ebengreuth, The Lancet Oncology Zoledronic AcidBreast OncologyBone HealthAdjuvant Endocrine TherapyMedicine	2008	393
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone Michael Gnant, Martin Filipits, Richard Greil, Annals of Oncology Surgical OncologyBreast OncologyRecurrence ScoreDistant RecurrenceCancer Recurrence	2013	392
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 Michael Gnant, Brigitte Mlineritsch, Herbert Stoeger, Annals of Oncology Zoledronic AcidBreast OncologyEndocrine OncologyMedicinePharmacology	2014	300
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study Erica L. Mayer, Amylou C. Dueck, Miguel Martín, The Lancet Oncology Interim AnalysisEndocrine OncologyBreast OncologyOncologyEarly Breast Cancer	2021	250
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial Michael Gnant, Georg Pfeiler, Günther Steger, The Lancet Oncology Breast OncologyMedicineClinical TrialsAdjuvant DenosumabDisease-free Survival Results	2019	231
Impact of Breast Surgery in Primary Metastasized Breast Cancer Florian Fitzal, Vesna Bjelic‐Radisic, Michael Knauer, Annals of Surgery	2018	199
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 Giuseppe Curigliano, Harold J. Burstein, Michael Gnant, Annals of Oncology	2023	189

Page 1